Press Releases HUTCHMED (China) Limited

Equities

HCM

KYG4672N1198

Market Closed - London S.E. Other stock markets 11:35:00 2024-06-06 am EDT			5-day change	1st Jan Change
290 ^GBX	-0.34%		-2.68%	+2.47%

Jun. 03	HUTCHMED Limited Highlights Publication of Phase III FRUTIGA Results in Nature Medicine	CI
May. 24	HUTCHMED Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be presented at the upcoming EHA2024 Congress	May. 20	AQ
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda	Apr. 29	AQ
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status	Apr. 03	AQ
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China	Mar. 21	AQ
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session	Feb. 06	AQ
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership	Feb. 02	AQ
HUTCHMED to Announce 2023 Final Results	Feb. 01	AQ
Chronic Myelomonocytic Leukaemia Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)	Dec. 20	AQ
HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms	Dec. 12	AQ
HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China	Dec. 12	AQ
HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses	Nov. 30	AQ
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023	23-10-16	AQ
HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan	23-09-29	AQ
HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer	23-09-12	AQ
HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer	23-08-28	AQ
HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China	23-08-20	AQ
HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study	23-07-19	AQ
HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China	23-07-09	AQ
HUTCHMED to Announce 2023 Half-Year Financial Results	23-06-26	AQ
HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet	23-06-15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases HUTCHMED (China) Limited

Equities

HCM

KYG4672N1198

Press Releases

Filters